What is Lifesci Capital's Estimate for OLMA FY2025 Earnings?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Equities researchers at Lifesci Capital cut their FY2025 earnings per share estimates for Olema Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings per share of ($2.28) for the year, down from their previous estimate of ($2.12). The consensus estimate for Olema Pharmaceuticals' current full-year earnings is ($2.33) per share.

A number of other analysts have also weighed in on OLMA. Oppenheimer restated an "outperform" rating and set a $25.00 target price (down previously from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th.

Olema Pharmaceuticals Stock Down 3.0 %

Shares of NASDAQ OLMA traded down $0.13 during midday trading on Friday, reaching $4.19. 541,869 shares of the company's stock traded hands, compared to its average volume of 817,554. The company has a market cap of $240.08 million, a price-to-earnings ratio of -1.91 and a beta of 2.11. The stock's 50 day simple moving average is $5.06 and its 200-day simple moving average is $8.20. Olema Pharmaceuticals has a one year low of $3.94 and a one year high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.12.

Remove Ads

Insider Activity at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of the company's stock in a transaction that occurred on Wednesday, January 8th. The shares were purchased at an average cost of $5.76 per share, for a total transaction of $1,728,000.00. Following the purchase, the insider now directly owns 7,800,000 shares in the company, valued at $44,928,000. This represents a 4.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 19.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its position in shares of Olema Pharmaceuticals by 52.1% in the 4th quarter. Wellington Management Group LLP now owns 1,525,484 shares of the company's stock valued at $8,839,000 after purchasing an additional 522,799 shares during the last quarter. Polar Asset Management Partners Inc. purchased a new position in shares of Olema Pharmaceuticals in the fourth quarter worth $119,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Olema Pharmaceuticals by 23.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 93,979 shares of the company's stock worth $548,000 after buying an additional 18,005 shares during the last quarter. Squarepoint Ops LLC lifted its stake in shares of Olema Pharmaceuticals by 205.8% during the fourth quarter. Squarepoint Ops LLC now owns 48,829 shares of the company's stock worth $285,000 after buying an additional 32,860 shares during the period. Finally, ProShare Advisors LLC grew its holdings in shares of Olema Pharmaceuticals by 30.2% during the fourth quarter. ProShare Advisors LLC now owns 14,226 shares of the company's stock valued at $83,000 after buying an additional 3,298 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.